Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...

Nelson Peltz’s Trian Fund Management plans to push Solventum (SOLV) to separate more of its businesses after the company sold its filtration ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

The most notable increase was Solventum Corp (NYSE:SOLV), with an additional 1,336,564 shares, bringing the total to 8,462,819 shares. This adjustment represents a significant 18.76% increase in share ...

Its stock is up 12% so far this year. Solventum Corporation (NYSE:SOLV) is a spinoff from 3M Company (MMM) and is currently ...

Nelson Peltz’s Trian Partners sent a letter to the shareholders of Solventum (SOLV), saying the company trades at a discount to peers and 3M (MMM), Scott Wapner of CNBC reports. Trian believes ...

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company’s $4.1 billion deal to sell its filtration ...

Nelson Peltz's Trian Fund Management Reshaped Portfolio ... to bring significant economic policy shifts. Henry Khederian Solventum Shares May Gain on the Launch of Its New V.A.C Therapy Solventum ...

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...